Edgar Jacoby
Edgar Jacoby has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Berthold Wroblowski
Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium
2 shared publicationsChristophe Buyck
Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium
2 shared publications- Daniela Digles
University of Vienna, Department of Pharmaceutical Sciences
2 shared publications - Herman van Vlijmen
Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium
2 shared publications A. Caracoti
D BIOVIA , a Dassault Systèmes brand , 334 Cambridge Science Park , Cambridge CB4 0WN , UK
1 shared publicationA. Wollmer
1 shared publication
Latest Publications
- 26 May 2026
- Published by Elsevier in Antiviral Research
- Vol. 251, 106440
Targeting dengue virus envelope protein: Insights from structural analysis and high-throughput screening
- 26 May 2026
- Published by Elsevier in Antiviral Research
- Vol. 251, 106440
Targeting dengue virus envelope protein: Insights from structural analysis and high-throughput screening
- Open Access
- 11 June 2020
- Published by Taylor & Francis in Future Drug Discovery
- Vol. 2 (3)
FEP+ calculations predict a stereochemical SAR switch for first-in-class indoline NIK inhibitors for multiple myeloma
In the search for first-in-class NIK inhibitors for multiple myeloma, we discovered an azaindoline hit class generated from a biochemical NIK autophosphorylation high-throughput screening assay whi...
- 11 June 2020
- Published by Taylor & Francis in Future Drug Discovery
- Vol. 2 (3)
Open AccessFEP+ calculations predict a stereochemical SAR switch for first-in-class indoline NIK inhibitors for multiple myeloma
In the search for first-in-class NIK inhibitors for multiple myeloma, we discovered an azaindoline hit class generated from a biochemical NIK autophosphorylation high-throughput screening assay whi...
- 18 October 2018
- Published by Springer Nature
- Vol. 1825, 425-450
The Future of Computational Chemogenomics
Following the elucidation of the human genome, chemogenomics emerged in the beginning of the twenty-first century as an interdisciplinary research field with the aim to accelerate target and drug discovery by making best usage of the genomic data and the data linkable to it. What started as a systematization approach within protein target families now encompasses all types of chemical compounds and gene products. A key objective of chemogenomics is the establishment, extension, analysis, and prediction of a comprehensive SAR matrix which by application will enable further systematization in drug discovery. Herein we outline future perspectives of chemogenomics including the extension to new molecular modalities, or the potential extension beyond the pharma to the agro and nutrition sectors, and the importance for environmental protection. The focus is on computational sciences with potential applications for compound library design, virtual screening, hit assessment, analysis of phenotypic screens, lead finding and optimization, and systems biology-based prediction of toxicology and translational research.
- 18 October 2018
- Published by Springer Nature
- Vol. 1825, 425-450
The Future of Computational Chemogenomics
Following the elucidation of the human genome, chemogenomics emerged in the beginning of the twenty-first century as an interdisciplinary research field with the aim to accelerate target and drug discovery by making best usage of the genomic data and the data linkable to it. What started as a systematization approach within protein target families now encompasses all types of chemical compounds and gene products. A key objective of chemogenomics is the establishment, extension, analysis, and prediction of a comprehensive SAR matrix which by application will enable further systematization in drug discovery. Herein we outline future perspectives of chemogenomics including the extension to new molecular modalities, or the potential extension beyond the pharma to the agro and nutrition sectors, and the importance for environmental protection. The focus is on computational sciences with potential applications for compound library design, virtual screening, hit assessment, analysis of phenotypic screens, lead finding and optimization, and systems biology-based prediction of toxicology and translational research.
- 8 May 2018
- Published by Springer Nature
- Vol. 1787, 183-193
Accessing the Open PHACTS Discovery Platform with Workflow Tools
The Open PHACTS Discovery Platform integrates several public databases, which can be of interest when annotating the results of a phenotypic screening campaign. Workflow tools provide easy-to-customize possibilities to access the platform. Here, we describe how to create such workflows for two different workflow tools (KNIME and Pipeline Pilot), including a protocol to annotate compounds (e.g., phenotypic screening hits) with compound classification, known protein targets, and classifications of the targets.
- 8 May 2018
- Published by Springer Nature
- Vol. 1787, 183-193
Accessing the Open PHACTS Discovery Platform with Workflow Tools
The Open PHACTS Discovery Platform integrates several public databases, which can be of interest when annotating the results of a phenotypic screening campaign. Workflow tools provide easy-to-customize possibilities to access the platform. Here, we describe how to create such workflows for two different workflow tools (KNIME and Pipeline Pilot), including a protocol to annotate compounds (e.g., phenotypic screening hits) with compound classification, known protein targets, and classifications of the targets.
- 8 November 2017
- Published by Wiley in Molecular Informatics
- Vol. 37 (5) , e1700119
Protocols for the Design of Kinase‐focused Compound Libraries
Protocols for the design of kinase‐focused compound libraries are presented. Kinase‐focused compound libraries can be differentiated based on the design goal. Depending on whether the library should be a discovery library specific for one particular kinase, a general discovery library for multiple distinct kinase projects, or even phenotypic screening, there exists today a variety of in silico methods to design candidate compound libraries. We address the following scenarios: 1) Datamining of SAR databases and kinase focused vendor catalogues; 2) Predictions and virtual screening; 3) Structure‐based design of combinatorial kinase inhibitors; 4) Design of covalent kinase inhibitors; 5) Design of macrocyclic kinase inhibitors; and 6) Design of allosteric kinase inhibitors and activators.
- 8 November 2017
- Published by Wiley in Molecular Informatics
- Vol. 37 (5) , e1700119
Protocols for the Design of Kinase‐focused Compound Libraries
Protocols for the design of kinase‐focused compound libraries are presented. Kinase‐focused compound libraries can be differentiated based on the design goal. Depending on whether the library should be a discovery library specific for one particular kinase, a general discovery library for multiple distinct kinase projects, or even phenotypic screening, there exists today a variety of in silico methods to design candidate compound libraries. We address the following scenarios: 1) Datamining of SAR databases and kinase focused vendor catalogues; 2) Predictions and virtual screening; 3) Structure‐based design of combinatorial kinase inhibitors; 4) Design of covalent kinase inhibitors; 5) Design of macrocyclic kinase inhibitors; and 6) Design of allosteric kinase inhibitors and activators.
- Open Access
- 11 May 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (6) , 1237-1244
Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns
Phenotypic screening is in a renaissance phase and is expected by many academic and industry leaders to accelerate the discovery of new drugs for new biology. Given that phenotypic screening is per definition target agnostic, the emphasis of in silico and in vitro follow-up work is on the exploration of possible molecular mechanisms and efficacy targets underlying the biological processes interrogated by the phenotypic screening experiments. Herein, we present six exemplar computational protocols for the interpretation of cellular phenotypic screens based on the integration of compound, target, pathway, and disease data established by the IMI Open PHACTS project. The protocols annotate phenotypic hit lists and allow follow-up experiments and mechanistic conclusions. The annotations included are from ChEMBL, ChEBI, GO, WikiPathways and DisGeNET. Also provided are protocols which select from the IUPHAR/BPS Guide to PHARMACOLOGY interaction file selective compounds to probe potential targets and a correlation robot which systematically aims to identify an overlap of active compounds in both the phenotypic as well as any kinase assay. The protocols are applied to a phenotypic pre-lamin A/C splicing assay selected from the ChEMBL database to illustrate the process. The computational protocols make use of the Open PHACTS API and data and are built within the Pipeline Pilot and KNIME workflow tools.
- 11 May 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (6) , 1237-1244
Open AccessOpen PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns
Phenotypic screening is in a renaissance phase and is expected by many academic and industry leaders to accelerate the discovery of new drugs for new biology. Given that phenotypic screening is per definition target agnostic, the emphasis of in silico and in vitro follow-up work is on the exploration of possible molecular mechanisms and efficacy targets underlying the biological processes interrogated by the phenotypic screening experiments. Herein, we present six exemplar computational protocols for the interpretation of cellular phenotypic screens based on the integration of compound, target, pathway, and disease data established by the IMI Open PHACTS project. The protocols annotate phenotypic hit lists and allow follow-up experiments and mechanistic conclusions. The annotations included are from ChEMBL, ChEBI, GO, WikiPathways and DisGeNET. Also provided are protocols which select from the IUPHAR/BPS Guide to PHARMACOLOGY interaction file selective compounds to probe potential targets and a correlation robot which systematically aims to identify an overlap of active compounds in both the phenotypic as well as any kinase assay. The protocols are applied to a phenotypic pre-lamin A/C splicing assay selected from the ChEMBL database to illustrate the process. The computational protocols make use of the Open PHACTS API and data and are built within the Pipeline Pilot and KNIME workflow tools.
- 1 June 2015
- Published by Elsevier in Drug Discovery Today
- Vol. 20 (6) , 652-658
Extending kinome coverage by analysis of kinase inhibitor broad profiling data
- 1 June 2015
- Published by Elsevier in Drug Discovery Today
- Vol. 20 (6) , 652-658
Extending kinome coverage by analysis of kinase inhibitor broad profiling data
- Open Access
- 1 January 1991
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 4 (8) , 1021
A model for the C5a receptor and for its interaction with the ligand
A printer's error was introduced into the title of this article when it was in press. The correct title is as follows.
- 1 January 1991
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 4 (8) , 1021
Open AccessA model for the C5a receptor and for its interaction with the ligand
A printer's error was introduced into the title of this article when it was in press. The correct title is as follows.